eureKARE Lights Up the European Biotech Scene with a $60 M Series A
Long‑time guess‑work and the biggest
gap between European research and the big pharma game finally get a serious fix.
What’s the Big Deal?
- Microbiome & Synthetic Biology – two realms that could rewrite the whole life‑sciences playbook.
- Microbiome research is projected to hit $1.6 B by 2028 – that’s a 21 % CAGR.
- Synthetic biology is staring down a $57 B future (25 % CAGR) and already raking in $4 B in gene therapies.
Who’s Backing the Boom?
High‑net‑worth investors and family offices poured in the cash, backing the company’s two‑step strategy designed to hand European science a front‑row seat.
The Two‑Step Playbook
- Build startup studios – eureKABIOME for microbiome, eureKASYNBIO for synthetic biology – by hand‑picking top European projects, and turning them into thriving businesses.
- Invest later in more mature biotech firms (Series B and beyond), giving early investors exit chances and keeping risk at bay.
Plan: 3–5 new ventures per year + 3–5 existing companies – a sweet mix of fresh ideas and proven pipelines.
What’s Already on the Menu?
Three flagship ventures already sweeten the pot:
- Stellate Therapeutics – tackling the gut‑brain axis.
- Omne Possibile – a trailblazer in X‑NA technology.
- NovoBiome – a discovery platform zooming into the gut‑liver axis.
“We’re obsessed with thinking outside the box,” says CEO Rodolphe Besserve, “and the rapid whizz‑down of COVID vaccines teaches us that human ingenuity can speed the future forward.”
Leadership & Advisory Lights
Led by founder Alexandre Mouradian and a powerhouse board of eight international biotech luminaries, the company is poised to turn European brilliance into commercial triumphs.
Why Europe? Why Now?
Europe’s universities and research hubs are at the cutting edge of microbiome and synthetic biology. But the gap between academia and big pharma has been widening for years.
eureKARE’s mission: bridge that gap, nurture ideas from the lab to the shelf, and deliver stellar returns for investors and patients alike.
Bottom Line
If you’re watching biotech trends, keep your eyes on eureKARE. Their fresh portfolio, solid backing, and visionary leadership could well light the way to the next wave of life‑science revolutions.
